The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms
The Stryker Mako Robotic System uses artificial intelligence to improve surgical accuracy with real-time guidance, personalized planning, and precise execution
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
A triple-action Formula for comprehensive respiratory relief
Extended lab space for product development, customer demos, and training
Star Health Insurance is modernising its claims ecosystem to be future-ready
Subscribe To Our Newsletter & Stay Updated
